These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 25681022)

  • 1. Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study.
    Călugăru D; Călugăru M
    Am J Ophthalmol; 2015 Mar; 159(3):607-8. PubMed ID: 25681022
    [No Abstract]   [Full Text] [Related]  

  • 2. Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study.
    Ogura Y; Roider J; Korobelnik JF; Holz FG; Simader C; Schmidt-Erfurth U; Vitti R; Berliner AJ; Hiemeyer F; Stemper B; Zeitz O; Sandbrink R;
    Am J Ophthalmol; 2014 Nov; 158(5):1032-8. PubMed ID: 25068637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.
    Lotfy A; Solaiman KAM; Abdelrahman A; Samir A
    Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal ziv-aflibercept for recurrent macular edema secondary to central retinal venous occlusion.
    Chhablani J
    Indian J Ophthalmol; 2015 May; 63(5):469-70. PubMed ID: 26139820
    [No Abstract]   [Full Text] [Related]  

  • 5. The effect of switching ranibizumab to aflibercept in refractory cases of macular edema secondary to ischemic central vein occlusion.
    Lehmann-Clarke L; Dirani A; Mantel I; Ambresin A
    Klin Monbl Augenheilkd; 2015 Apr; 232(4):552-5. PubMed ID: 25902119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion.
    Saishin Y; Ito Y; Fujikawa M; Sawada T; Ohji M
    Jpn J Ophthalmol; 2017 Jan; 61(1):67-73. PubMed ID: 27660163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. INTRAVITREAL INJECTIONS OF ZIV-AFLIBERCEPT FOR THE TREATMENT OF A PATIENT WITH MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION.
    Andrade GC; Dias JRO; Maia A; Farah ME; Mitne S; Rodrigues EB
    Retin Cases Brief Rep; 2018 Spring; 12(2):93-96. PubMed ID: 29554051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study.
    Brown DM; Heier JS; Clark WL; Boyer DS; Vitti R; Berliner AJ; Zeitz O; Sandbrink R; Zhu X; Haller JA
    Am J Ophthalmol; 2013 Mar; 155(3):429-437.e7. PubMed ID: 23218699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data.
    Chatziralli I; Theodossiadis G; Moschos MM; Mitropoulos P; Theodossiadis P
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1093-1100. PubMed ID: 28214955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-year treatment outcomes of ziv-aflibercept for treatment-naïve macular oedema in branch retinal vein occlusion.
    Chan EW; Eldeeb M; Dedhia CJ; Mansour A; Chhablani J
    Acta Ophthalmol; 2018 Mar; 96(2):e256-e257. PubMed ID: 28371171
    [No Abstract]   [Full Text] [Related]  

  • 11. Aflibercept: A Review in Macular Oedema Secondary to Branch Retinal Vein Occlusion.
    Hoy SM
    Drugs Aging; 2017 May; 34(5):393-400. PubMed ID: 28365905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study.
    Korobelnik JF; Holz FG; Roider J; Ogura Y; Simader C; Schmidt-Erfurth U; Lorenz K; Honda M; Vitti R; Berliner AJ; Hiemeyer F; Stemper B; Zeitz O; Sandbrink R;
    Ophthalmology; 2014 Jan; 121(1):202-208. PubMed ID: 24084497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of switching treatment to aflibercept in patients with macular oedema secondary to central retinal vein occlusion refractory to ranibizumab.
    Konidaris V; Al-Hubeshy Z; Tsaousis KT; Gorgoli K; Banerjee S; Empeslidis T
    Int Ophthalmol; 2018 Feb; 38(1):207-213. PubMed ID: 28405787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reply: To PMID 25068637.
    Ogura Y; Roider J; Korobelnik JF; Holz FG; Simader C; Schmidt-Erfurth U; Vitti R; Berliner AJ; Hiemeyer F; Stemper B; Zeitz O; Sandbrink R;
    Am J Ophthalmol; 2015 Mar; 159(3):608. PubMed ID: 25681024
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of Intravitreal Ranibizumab, Aflibercept, and Dexamethasone Implant after Bevacizumab Failure in Macular Edema Secondary to Retinal Vascular Occlusions.
    Hanhart J; Rozenman Y
    Ophthalmologica; 2017; 238(1-2):110-118. PubMed ID: 28535531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cotton Wool Spots after Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Associated with Central Retinal Vein Occlusion.
    Kida T; Tsujikawa A; Muraoka Y; Harino S; Osaka R; Murakami T; Ooto S; Suzuma K; Morishita S; Fukumoto M; Suzuki H; Ikeda T
    Ophthalmologica; 2016; 235(2):106-13. PubMed ID: 26800210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study.
    Heier JS; Clark WL; Boyer DS; Brown DM; Vitti R; Berliner AJ; Kazmi H; Ma Y; Stemper B; Zeitz O; Sandbrink R; Haller JA
    Ophthalmology; 2014 Jul; 121(7):1414-1420.e1. PubMed ID: 24679444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New perspectives in the approach to central retinal vein occlusion].
    Figueroa MS
    Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():15-23. PubMed ID: 25925047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to aflibercept as secondary therapy in patients with persistent retinal edema due to central retinal vein occlusion initially treated with bevacizumab or ranibizumab.
    Eadie JA; Ip MS; Kulkarni AD
    Retina; 2014 Dec; 34(12):2439-43. PubMed ID: 24999721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive Review of Ocular and Systemic Safety Events with Intravitreal Aflibercept Injection in Randomized Controlled Trials.
    Kitchens JW; Do DV; Boyer DS; Thompson D; Gibson A; Saroj N; Vitti R; Berliner AJ; Kaiser PK
    Ophthalmology; 2016 Jul; 123(7):1511-20. PubMed ID: 27084563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.